Document Type
Article
Version Deposited
Published Version
Publication Date
3-8-2023
Publication Title
Pharmaceuticals (Basel)
DOI
10.3390/ph16030415
Abstract
Multiple myeloma (MM) is a challenging hematological cancer which typically grows in bone marrow. MM accounts for 10% of hematological malignancies and 1.8% of cancers. The recent treatment strategies have significantly improved progression-free survival for MM patients in the last decade; however, a relapse for most MM patients is inevitable. In this review we discuss current treatment, important pathways for proliferation, survival, immune suppression, and resistance that could be targeted for future treatments.
Recommended Citation
Elbezanti, W.O.; Challagundla, K.B.; Jonnalagadda, S.C.; Budak-Alpdogan, T.; Pandey, M.K. Past, Present, and a Glance into the Future of Multiple Myeloma Treatment. Pharmaceuticals 2023, 16, 415. https://doi.org/10.3390/ph16030415
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Comments
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.